The current stock price of ATON is 0.9169 USD. In the past month the price decreased by -16.65%.
ChartMill assigns a fundamental rating of 1 / 10 to ATON. Both the profitability and financial health of ATON have multiple concerns.
Over the last trailing twelve months ATON reported a non-GAAP Earnings per Share(EPS) of -5.72. The EPS increased by 92.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -304.13% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.48 | 392.16B | ||
| AMGN | AMGEN INC | 15.04 | 177.14B | ||
| GILD | GILEAD SCIENCES INC | 15.15 | 153.93B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.89 | 114.05B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.75 | 79.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 719.33 | 48.47B | ||
| INSM | INSMED INC | N/A | 34.86B | ||
| NTRA | NATERA INC | N/A | 33.01B | ||
| BIIB | BIOGEN INC | 10.11 | 24.84B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.03 | 20.48B | ||
| INCY | INCYTE CORP | 16.5 | 20.80B |
AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. The firm is focused on building and managing a strategic reserve of The Open Network (TON) tokens and developing the Telegram ecosystem. The firm implements a treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, the Company provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform. The company is also advancing therapies that target known checkpoint resistance pathways to achieve durable treatment response and improve quality of life for patients. The firm engages in the drug development process and provides strategic counsel to guide development of immunotherapy assets and asset combinations.
ALPHATON CAPITAL CORP
Clarence Thomas Building, P.O. Box 4649, Road Town
Tortola ONTARIO VG
Employees: 3
Phone: 4167377600
AlphaTON Capital Corp. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. The firm is focused on building and managing a strategic reserve of The Open Network (TON) tokens and developing the Telegram ecosystem. The firm implements a treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, the Company provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform. The company is also advancing therapies that target known checkpoint resistance pathways to achieve durable treatment response and improve quality of life for patients. The firm engages in the drug development process and provides strategic counsel to guide development of immunotherapy assets and asset combinations.
The current stock price of ATON is 0.9169 USD. The price decreased by -29.47% in the last trading session.
ATON does not pay a dividend.
ATON has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
ALPHATON CAPITAL CORP (ATON) currently has 3 employees.
ALPHATON CAPITAL CORP (ATON) has a market capitalization of 7.00M USD. This makes ATON a Nano Cap stock.